Activities per year
Project Details
Description (abstract)
Drug screening investigating the ability of epigenetic inhibitors to modulate the chromatin structure and reprogram therapy-resistant cancer cells into sensitive ones. Our screening tested 60 epigenetic compounds on four R-CHOP resistant DLBCL cell lines.
| Status | Finished |
|---|---|
| Effective start/end date | 04/08/2014 → 11/12/2019 |
Activities
- 1 Invited talk
-
Drug resistance and DLBCL: an epigenetic reprogramming story
Julia Casado Cuervo (Speaker)
13 Dec 2016Activity: Talk or presentation types › Invited talk